Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Therapy Insight: heart disease and the insulin-resistant patient

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 252–260 (2005)Cite this article

Abstract

Insulin-resistance syndromes are of pandemic proportions; 150 million people worldwide and an estimated 43 million people in the US are currently affected by type 2 diabetes mellitus or metabolic syndrome respectively. Treatment of heart disease in the context of type 2 diabetes requires multifactorial risk-factor management, including lifestyle modification and drug treatment for comorbidities. Management of coronary risk extends beyond simple cholesterol lowering. Early use of cardiac imaging and, where appropriate, revascularization should be considered in high-risk or symptomatic patients. Traditionally, patients with type 2 diabetes and coronary arterial disease have been treated surgically, but percutaneous revascularization of these patients is increasingly common. Indeed, revascularization by use of drug-eluting coronary stents combined with administration of novel antiplatelet agents has revolutionized percutaneous coronary intervention in patients with type 2 diabetes. Despite these advances, there is no consensus of opinion regarding revascularization strategies or risk-factor management in insulin-resistant patients with symptomatic or prognostically important coronary arterial disease. Furthermore, specific therapies and preventative strategies for diabetic cardiomyopathy and heart failure in patients with type 2 diabetes remain elusive. The identification of optimized approaches for the prevention and treatment of the metabolic syndrome and heart disease in insulin-resistant, nondiabetic patients remains a major global challenge.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Cellular mechanisms of insulin resistance.

References

  1. Reaven GM (1988) Banting lecture. Role of insulin resistance in human disease. Diabetes 37: 1595–1607

    Article  CAS  Google Scholar 

  2. Lorenzo C et al. (2003) The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26: 3153–3159

    Article  Google Scholar 

  3. Zimmet P et al. (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782–787

    Article  CAS  Google Scholar 

  4. Ford ES et al. (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356–359

    Article  Google Scholar 

  5. Ninomiya JK et al. (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109: 42–46

    Article  Google Scholar 

  6. Nathan DM et al. (1997) The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? Lancet 350 (Suppl 1): SI4–SI9

    Article  Google Scholar 

  7. Grundy SM et al. (1999) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134–1146

    Article  CAS  Google Scholar 

  8. Kannel WB and McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035–2038

    Article  CAS  Google Scholar 

  9. Bergman RN et al. (1979) Quantitative estimation of insulin sensitivity. Am J Physiol 236: E667–E677

    CAS  PubMed  Google Scholar 

  10. Matthews DR et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419

    Article  CAS  Google Scholar 

  11. DeFronzo RA (1988) 1987 Lilly lecture. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667–687

    Article  CAS  Google Scholar 

  12. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106: 171–176

    Article  CAS  Google Scholar 

  13. Randle PJ et al. (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785–789

    Article  CAS  Google Scholar 

  14. Aitman TJ et al. (1997) Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 17: 748–754

    Article  CAS  Google Scholar 

  15. Paternostro G et al. (1996) Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest 98: 2094–2099

    Article  CAS  Google Scholar 

  16. Schumacher MC et al. (1992) Major gene effect for insulin levels in familial NIDDM pedigrees. Diabetes 41: 416–423

    Article  CAS  Google Scholar 

  17. Shoulders CC et al. (2004) Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 13 (Spec 1): R149–R160

    Article  Google Scholar 

  18. Aitman TJ and Todd JA (1995) Molecular genetics of diabetes mellitus. Baillieres Clin Endocrinol Metab 9: 631–656

    Article  CAS  Google Scholar 

  19. Stern MP (2000) Strategies and prospects for finding insulin resistance genes. J Clin Invest 106: 323–327

    Article  CAS  Google Scholar 

  20. Kahn BB and Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106: 473–481

    Article  CAS  Google Scholar 

  21. Grundy SM et al. (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433–438

    Article  Google Scholar 

  22. Haffner SM et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234

    Article  CAS  Google Scholar 

  23. James RW (2001) Diabetes and other coronary heart disease risk equivalents. Curr Opin Lipidol 12: 425–431

    Article  CAS  Google Scholar 

  24. Thrainsdottir IS et al. (2005) The association between glucose abnormalities and heart failure in the population-based reykjavik study. Diabetes Care 28: 612–616

    Article  Google Scholar 

  25. Bauters C et al. (2003) Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2: 1

    Article  Google Scholar 

  26. Creager MA et al. (2003) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108: 1527–1532

    Article  Google Scholar 

  27. Young ME et al. (2002) Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 105: 1861–1870

    Article  CAS  Google Scholar 

  28. Nitenberg A et al. (2002) Coronary microvascular adaptation to myocardial metabolic demand can be restored by inhibition of iron-catalyzed formation of oxygen free radicals in type 2 diabetic patients. Diabetes 51: 813–818

    Article  CAS  Google Scholar 

  29. Rutter MK et al. (2003) Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107: 448–454

    Article  CAS  Google Scholar 

  30. Rubler S et al. (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30: 595–602

    Article  CAS  Google Scholar 

  31. Taegtmeyer H et al. (2002) Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 105: 1727–1733

    Article  CAS  Google Scholar 

  32. Mizushige K et al. (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101: 899–907

    Article  CAS  Google Scholar 

  33. (online 31 March 2005) Department of Health [http://www.dh.gov.uk] (accessed 31 March 2005)

  34. Tuomilehto J et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350

    Article  CAS  Google Scholar 

  35. Knowler WC et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 346: 393–403

    Article  CAS  Google Scholar 

  36. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253–259

  37. Hansson L et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762

    Article  CAS  Google Scholar 

  38. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853

  39. Williams B et al. (2004) Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18: 139–185

    Article  CAS  Google Scholar 

  40. Steinmetz A et al. (2001) Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 109: S548–S559

    Article  CAS  Google Scholar 

  41. Steiner G (2000) Lipid intervention trials in diabetes. Diabetes Care 23 (Suppl 2): B49–B53

    PubMed  Google Scholar 

  42. Colhoun HM et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685–696

    Article  CAS  Google Scholar 

  43. Bays H (2002) Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol 90: 30K–43K

    Article  CAS  Google Scholar 

  44. Rubins HB et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410–418

    Article  CAS  Google Scholar 

  45. Robins SJ et al. (2003) Insulin resistance and cardiovascular events with low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) Diabetes Care 26: 1513–1517

    Article  CAS  Google Scholar 

  46. Brown BG et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583–1592

    Article  CAS  Google Scholar 

  47. Garg A and Grundy SM (1990) Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264: 723–726

    Article  CAS  Google Scholar 

  48. Brousseau ME et al. (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505–1515

    Article  CAS  Google Scholar 

  49. Krentz AJ and Bailey CJ (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65: 385–411

    Article  CAS  Google Scholar 

  50. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865

  51. Chiasson JL et al. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM Trial. JAMA 290: 486–494

    Article  CAS  Google Scholar 

  52. Hallsten K et al. (2004) Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med 21: 1280–1287

    Article  CAS  Google Scholar 

  53. Zuckerman SH et al. (2002) Peroxisome proliferator-activated receptor alpha, gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids 37: 487–494

    Article  CAS  Google Scholar 

  54. BARI1 (1996) Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 335: 217–225

  55. Beatt KJ et al. (2004) Revascularisation in diabetics with multivessel coronary artery disease. Heart 90: 999–1002

    Article  CAS  Google Scholar 

  56. Leon MB and Bakhai A (2003) Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future. Am Heart J 146 (Suppl): S13–S17

    Article  CAS  Google Scholar 

  57. Kapur A et al. (2005) The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J 149: 13–19

    Article  CAS  Google Scholar 

  58. Sobel BE et al. (2003) Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 107: 636–642

    Article  Google Scholar 

  59. Marso SP et al. (2003) Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. Am Heart J 145: 270–277

    Article  Google Scholar 

  60. Miettinen H et al. (1998) Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21: 69–75

    Article  CAS  Google Scholar 

  61. Bartnik M et al. (2004) Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 25: 1990–1997

    Article  CAS  Google Scholar 

  62. Malmberg K et al. (1995) Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26: 57–65

    Article  CAS  Google Scholar 

  63. Malmberg K et al. (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26: 650–661

    Article  CAS  Google Scholar 

  64. Keeley EC et al. (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361: 13–20

    Article  Google Scholar 

  65. Underwood SR et al. (2004) Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 25: 815–836

    Article  Google Scholar 

  66. Fonarow GC (2004) Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 116 (Suppl 5A): 76S–88S

    Article  Google Scholar 

  67. Shekelle PG et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41: 1529–1538

    Article  CAS  Google Scholar 

  68. Packer M et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658

    Article  CAS  Google Scholar 

  69. Alberti KG and Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are supported by grants from the UK Department of Health, the Medical Research Council, the Wellcome Trust and the British Heart Foundation.

Author information

Authors and Affiliations

  1. Lecturer in Clinical Cardiology at the Imperial College Faculty of Medicine, London, UK

    Stuart A Cook

  2. Professor of Clinical & Molecular Genetics at the Imperial College Faculty of Medicine, Section Chair at the Medical Research Council Clinical Sciences Centre and an honorary Consultant Physician at Hammersmith Hospital, London, UK

    Tim Aitman

  3. Senior Clinical Scientist at the Medical Research Council Clinical Sciences Centre and honorary Consultant Physician at Hammersmith Hospital, London, UK

    Rossi P Naoumova

Authors
  1. Stuart A Cook
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tim Aitman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rossi P Naoumova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart A Cook.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Glossary

EUGLYCEMIC CLAMP TECHNIQUE

Insulin is infused at a constant rate and glucose titrated to a preset level. Insulin resistance is measured when a steady state is reached

HOMEOSTATIC MODEL ASSESSMENT

Uses fasting blood levels of insulin and glucose to model insulin resistance and β-cell function

MINIMAL MODEL ANALYSIS

Profiles of insulin and glucose concentrations after an intravenous glucose bolus are used to estimate insulin resistance and β-cell function by curve fitting

ORAL GLUCOSE TOLERANCE TEST

Plasma glucose levels are measured after oral consumption of 75 g anhydrous glucose in 250–300 ml of water. Raised glucose levels indicate impaired glucose tolerance

ADIPOKINES

Small proteins secreted from adipocytes which act on peripheral tissues to induce receptor-mediated activation of cellular signaling

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cook, S., Aitman, T. & Naoumova, R. Therapy Insight: heart disease and the insulin-resistant patient. Nat Rev Cardiol 2, 252–260 (2005). https://doi.org/10.1038/ncpcardio0194

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0194

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing